The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a more substantial loss in body